1. Phase 2 SPRING trial shows nebokitug's potential for PSC treatment. 2. Nebokitug demonstrated safety and tolerability through 48 weeks. 3. Significant biomarker improvements suggest disease-modifying effects. 4. Next step includes advancing to a Phase 3 clinical trial. 5. Nebokitug received FDA Fast Track and Orphan Drug designations.
FAQ
Why Bullish?
The positive SPRING trial results bolster investor confidence in CMMB's potential growth. Historical trends show stock gains following successful trial results.
How important is it?
The strong Phase 2 trial outcomes are crucial for developing CMMB's strategic market position and attracting investments.
Why Long Term?
As CMMB advances to Phase 3 trials, potential FDA approval becomes imminent, influencing long-term stock value positively.
Chemomab Therapeutics Publishes Phase 2 SPRING Trial Results in American Journal of Gastroenterology
On December 2, 2025, Chemomab Therapeutics Ltd. (NASDAQ: CMMB), a clinical-stage biotechnology company focused on treating fibro-inflammatory diseases, announced significant findings from its Phase 2 SPRING trial. The trial evaluated nebokitug in patients diagnosed with primary sclerosing cholangitis (PSC), with results recently published in the American Journal of Gastroenterology. The study not only confirmed the treatment's safety and tolerability over 48 weeks but also revealed promising improvements in several biomarkers associated with inflammation and fibrosis.
Study Overview and Implications
The Phase 2 SPRING trial demonstrated that patients receiving nebokitug experienced notable improvements in clinical markers, particularly among those dosed at 20 mg/kg. These positive outcomes highlight the potential of nebokitug as a future therapy for PSC, paving the way for a forthcoming Phase 3 registration trial.
Dr. Christopher Bowlus, Lena Valente Professor and Chief of the Division of Gastroenterology at UC Davis and lead author of the publication, commented, “The SPRING trial illustrated that nebokitug may transform the lives of PSC patients by effectively reducing fibrosis and inflammation, thus improving patient outcomes. The positive clinical findings and Chemomab’s trajectory toward a Phase 3 trial are significant for patients in need of viable treatments.”
Understanding Primary Sclerosing Cholangitis
Primary sclerosing cholangitis is a rare and progressive liver disease characterized by inflammation, fibrosis, and bile duct damage, often leading to serious complications such as biliary cirrhosis and early mortality. Currently, effective treatment options are limited, with liver transplantation being the primary solution for advanced cases.
Chemomab's approach with nebokitug targets the underlying pathological processes of PSC and aims to provide anti-inflammatory and anti-fibrotic effects, offering hope for enhanced clinical outcomes.
Details on Nebokitug and CCL24
Nebokitug is a humanized IgG1 anti-CCL24 monoclonal antibody that regulates inflammatory and fibrotic activities through mechanisms involving the CCR3 receptor, found on various cell types. Elevated levels of CCL24 have been identified in liver biopsies from PSC patients, indicating its relevance in PSC pathophysiology.
Therapeutic benefits of inhibiting CCL24 with nebokitug have been substantiated across various experimental PSC models, showcasing its potential for influencing disease progression positively.
SPRING Trial Design and Results
The SPRING trial was a double-blind, placebo-controlled study that included 76 participants across 33 sites in the US, UK, Germany, Spain, and Israel. Patients were randomized to receive either nebokitug (10 mg/kg or 20 mg/kg) or a placebo every three weeks for 15 weeks, followed by an optional open-label extension phase for up to 48 weeks.
Overall, nebokitug demonstrated a favorable safety profile with no significant safety concerns up to 48 weeks. Key findings included:
- Improvement in ELF Score: Patients receiving 20 mg/kg of nebokitug showed a numerical reduction in ELF score after 15 weeks, indicating potential benefits in transplant-free survival rates.
- Reduction in PRO-C3 Levels: Patients treated with nebokitug also exhibited sustained reductions in the PRO-C3 biomarker, linking it to fibrosis progression.
- Liver Stiffness Measurement (LSM): Nebokitug-treated patients had statistically significant improvements in LSM, suggesting a decrease in disease progression rates.
The trial’s outcomes suggest that treatments targeting multiple biomarkers can enhance the evidence for nebokitug’s efficacy, underscoring its role in the management of PSC.
Future Directions for Chemomab (CMMB)
As Chemomab prepares for the next steps, including a Phase 3 trial for nebokitug, the positive results from the SPRING trial represent a critical advance in therapies for PSC. The company aims to address the significant unmet needs within this patient population, leveraging both scientific innovation and clinical research to pave the way for new treatment developments.